Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Registry of Sarcoidosis Associated Pulmonary Hypertension (RESAPH) (RESAPH)

This study is currently recruiting participants. (see Contacts and Locations)
Verified December 2015 by University of Cincinnati
The Cleveland Clinic
Information provided by (Responsible Party):
Robert P Baughman, University of Cincinnati Identifier:
First received: November 4, 2011
Last updated: December 4, 2015
Last verified: December 2015
Registry to follow patients with sarcoidosis associated pulmonary hypertension

Condition Intervention
Pulmonary Hypertension
Other: Observation

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Registry of Sarcoidosis Associated Pulmonary Hypertension (RESAPH)

Resource links provided by NLM:

Further study details as provided by University of Cincinnati:

Primary Outcome Measures:
  • Survival [ Time Frame: 4 years ]
    Mortality during time of study

Secondary Outcome Measures:
  • Disease management [ Time Frame: 4 years ]
    Examine initial and follow up management

Biospecimen Retention:   Samples Without DNA
Serum samples

Estimated Enrollment: 300
Study Start Date: November 2011
Estimated Study Completion Date: January 2018
Estimated Primary Completion Date: January 2017 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
All patients with sarcoidosis associated pulmonary hypertension
Other: Observation
Observe patients

Detailed Description:
This is a multi center registry of sarcoidosis associated pulmonary hypertension (SAPH). With this registry, the investigators will characterize the demographics, clinical course, hemodynamics, pulmonary physiology, and disease management of sarcoidosis associated pulmonary hypertension on the United States. The investigators will also compare these features to non-US sites.

Ages Eligible for Study:   18 Years to 100 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients with sarcoidosis associated pulmonary hypertension

Inclusion Criteria:

  • Patients with sarcoidosis as defined by the ATS/WASOG statement
  • Patients with pulmonary hypertension as confirmed by right heart catheterization
  • Patients willing to provide written informed consent

Exclusion Criteria:

  • Unwillingness to provide assurance that they will complete the follow up visits for the study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01467791

Contact: Robert P Baughman, MD 513-584-5225
Contact: Rebecca Ingledue 513-584-6252

United States, Ohio
University of Cincinnati Recruiting
Cincinnati, Ohio, United States, 45267
Contact: Rebecca Ingledue    513-584-6252   
Principal Investigator: Robert P Baughman, MD         
Sub-Investigator: Peter Engel, MD         
Sponsors and Collaborators
University of Cincinnati
The Cleveland Clinic
Study Chair: Robert P Baughman, MD University of Cincinnati
  More Information

Responsible Party: Robert P Baughman, Professor of Medicine, University of Cincinnati Identifier: NCT01467791     History of Changes
Other Study ID Numbers: RESAPH 1
Study First Received: November 4, 2011
Last Updated: December 4, 2015

Keywords provided by University of Cincinnati:

Additional relevant MeSH terms:
Hypertension, Pulmonary
Vascular Diseases
Cardiovascular Diseases
Lung Diseases
Respiratory Tract Diseases
Lymphoproliferative Disorders
Lymphatic Diseases processed this record on May 24, 2017